Gottschlich S, Werner J A, Lippert B M, Görögh T, Maune S, Rudert H
Klinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Halschirurgie der Christian-Albrechts-Universität zu Kiel.
Laryngorhinootologie. 1995 Aug;74(8):508-11. doi: 10.1055/s-2007-997790.
Several investigations showed increased levels of the soluble interleukin-2 receptor (sIL-2 R) in chronic and malignant diseases. A correlation between elevated sIL-2 R levels and disease activity or tumor size was observed in some patients. At present, there are no studies of sIL-2 R serum levels in patients with squamous cell carcinomas of the upper aerodigestive tract.
SIL-2 R levels were measured in sera of 86 patients with squamous cell carcinoma of the head and neck and of 25 healthy controls with a sandwich ELISA.
Significantly elevated serum levels of sIL-2 R were detected in 49 out of 86 patients (56.9%) with squamous cell carcinoma of the head and neck. The mean serum level in the healthy controls was 437 U/ml compared to 895 U/ml in carcinoma patients. A correlation was found between tumor size, number of metastases and the sIL-2 R level. There was no correlation with histological type or tumor localization.
The physiological role of sIL-2 R is still unknown. Elevated levels of sIL-2 could be a sign of activation of the immune system. But they also might be involved in causing the disease. The sIL-2 R serum levels in patients with squamous cell carcinoma of the head and neck may serve as an unspecific indicator for tumor size and dissemination.
Posttherapeutic titer controls could be of prognostic value. Additionally, sIL-2 R may help to select appropriate patients for an immunotherapy with recombinant IL-2.
多项研究表明，慢性疾病和恶性疾病患者体内可溶性白细胞介素 - 2受体（sIL - 2R）水平升高。在一些患者中观察到sIL - 2R水平升高与疾病活动或肿瘤大小之间存在相关性。目前，尚无关于上呼吸道消化道鳞状细胞癌患者sIL - 2R血清水平的研究。
采用夹心酶联免疫吸附测定法（ELISA）检测了86例头颈部鳞状细胞癌患者和25例健康对照者血清中的sIL - 2R水平。
86例头颈部鳞状细胞癌患者中有49例（56.9%）血清sIL - 2R水平显著升高。健康对照者的平均血清水平为437 U/ml，而癌患者为895 U/ml。发现肿瘤大小、转移灶数量与sIL - 2R水平之间存在相关性。与组织学类型或肿瘤定位无关。
sIL - 2R的生理作用尚不清楚。sIL - 2水平升高可能是免疫系统激活的标志。但它们也可能参与疾病的发生。头颈部鳞状细胞癌患者的sIL - 2R血清水平可作为肿瘤大小和扩散的非特异性指标。
治疗后滴度控制可能具有预后价值。此外，sIL - 2R可能有助于选择合适的患者进行重组IL - 2免疫治疗。
